Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma

Bonertz A, Weitz J, Pietsch DH et al (2009) Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Investig 119:3311–3321

Brunn ND, Mauze S, Gu D et al (2016) The role of anti-drug antibodies in the pharmacokinetics, disposition, target engagement, and efficacy of a GITR agonist monoclonal antibody in mice. J Pharmacol Exp Ther 356:574–586

Bulliard Y, Jolicoeur R, Windman M et al (2013) Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210:1685–1693

Chao A, Chazdon RL, Colwell RK et al (2006) Abundance-based similarity indices and their estimation when there are unseen species in samples. Biometrics 62:361–371

Clouthier DL, Zhou AC, Watts TH (2014) Anti-GITR agonist therapy intrinsically enhances CD8 T cell responses to chronic lymphocytic choriomeningitis virus (LCMV), thereby circumventing LCMV-induced downregulation of costimulatory GITR ligand on APC. J Immunol 193:5033–5043

Coe D, Begom S, Addey C et al (2010) Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 59:1367–1377

Cohen AD, Schaer DA, Liu C et al (2010) Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 5:e10436

Darrasse-Jeze G, Bergot AS, Durgeau A et al (2009) Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Investig 119:2648–2662

Dittmer U, He H, Messer RJ et al (2004) Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity 20:293–303

Ephrem A, Epstein AL, Stephens GL et al (2013) Modulation of Treg cells/T effector function by GITR signaling is context-dependent. Eur J Immunol 43:2421–2429

Hindley JP, Ferreira C, Jones E et al (2011) Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res 71:736–746

Hu P, Arias RS, Sadun RE et al (2008) Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. Clin Cancer Res 14:579–588

Kim YH, Shin SM, Choi BK et al (2015) Authentic GITR signaling fails to induce tumor regression unless Foxp3+ regulatory T cells are depleted. J Immunol 195:4721–4729

Ko K, Yamazaki S, Nakamura K et al (2005) Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 202:885–891

Kuczma M, Pawlikowska I, Kopij M et al (2009) TCR repertoire and Foxp3 expression define functionally distinct subsets of CD4+ regulatory T cells. J Immunol 183:3118–3129

Kuczma M, Kopij M, Pawlikowska I et al (2010) Intratumoral convergence of the TCR repertoires of effector and Foxp3+CD4+T cells. PLoS One 5:e13623

Laszkiewicz A, Cebrat M, Miazek A et al (2011) Complexity of transcriptional regulation within the Rag locus: identification of a second Nwc promoter region within the Rag2 intron. Immunogenetics 63:183–187

Liao G, Nayak S, Regueiro JR et al (2010) GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells. Int Immunol 22:259–270

Liao G, O’Keeffe MS, Wang G et al (2014) Glucocorticoid-induced TNF receptor family-related protein-ligand is requisite for optimal functioning of regulatory CD4(+) T cells. Front Immunol 5:35

Murphy JT, Burey AP, Beebe AM et al (2014) Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood 123:2172–2180

Pacholczyk R, Ignatowicz H, Kraj P et al (2006) Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells. Immunity 25:249–259

Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D et al (2006) Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 176:6434–6442

Sainz-Perez A, Lim A, Lemercier B et al (2012) The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. Cancer Res 72:3557–3569

Schaer DA, Murphy JT, Wolchok JD (2012) Modulation of GITR for cancer immunotherapy. Curr Opin Immunol 24:217–224

Turk MJ, Guevara-Patino JA, Rizzuto GA et al (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200:771–782

van Olffen RW, Koning N, van Gisbergen KP et al (2009) GITR triggering induces expansion of both effector and regulatory CD4+ T cells in vivo. J Immunol 182:7490–7500